Inhibitex, Inc. (INHX)

[surf1944]

Buying Into a Hot Hepatitis C Drug Market

Inhibitex’s hepatitis C drug, INX-189, is being studied in the second of three phases of human trials generally needed for FDA approval. The treatment is part of a drug class known as nucleotide polymerase inhibitors. Public since 2004, the company also is studying a treatment for shingles, but Russo calls INX-189 “the real value driver.” He also says he believes Inhibitex will seek a partner to help develop the hepatitis drug.

http://www.minyanville.com/businessmarkets/articles/hepatitis-c-pharmasset-vertex-merck-johnson/8/25/2011/id/36565?camp=syndication&medium=portals&from=yahoo